Pirates reportedly on verge of acquiring reliever Camilo Doval from the Yankees

What happened

The Pittsburgh Pirates are reportedly on the verge of acquiring reliever Camilo Doval from the New York Yankees, per Ken Rosenthal on X, who cited a source. Jeff Passan broke the news first. As of the report, the deal remains in medical review — meaning neither club has made a formal announcement, and nothing about this transaction should be treated as complete.

Medical review is the stage at which a trade can still fall through. Until both organizations clear that process and issue a formal announcement, this is a deal in progress, not a finished one. The desk will treat it accordingly throughout.

Why it matters

The Pirates sit at 82-80 (.506), third in the NL Central, and have been eliminated from both the division race and the Wild Card race. That last part is worth sitting with for a moment. A club that has been mathematically removed from October contention is reportedly in the process of adding a reliever — which raises an honest question about what Pittsburgh is building toward in the final weeks of the season.

That said, roster construction does not stop when playoff math turns unfavorable. Teams continue to evaluate, acquire, and develop players through the end of the regular season, and a reliever with Doval's profile represents the kind of asset that can factor into future planning regardless of where the standings currently sit. Whether this move is about the remainder of 2026 or something further out is not something the report addresses.

What the report does establish is that the Pirates were active enough to get a deal to the medical review stage, which is not nothing. Reaching that point requires agreement on terms from both sides — the remaining uncertainty is procedural, not philosophical.

Is the deal done?

No. Per the reporting from Ken Rosenthal and Jeff Passan, the deal is in medical review. That stage exists precisely because trades are not final until both clubs have reviewed the relevant medical records and cleared them. A deal in medical review can be completed, restructured, or — in some cases — fall apart entirely. Until Pittsburgh or New York makes a formal announcement, this remains a reported transaction, not a completed one.

The numbers

Pittsburgh enters the weekend at 82-80 (.506), sitting third in the NL Central, 21 games back in the division. In the Wild Card picture, the Pirates rank fifth, 6.0 games relative to the cut line — and they have been eliminated from that race as well. They arrive at this moment on a one-game winning streak.

The schedule ahead does not offer much margin for error, though the standings have already rendered that somewhat academic. The Pirates are set to face the Cincinnati Reds on Saturday, August 1, with Braxton Ashcraft lined up against Andrew Abbott at Great American Ball Park. Sunday, August 2 brings Mitch Keller against Chase Burns in the same venue. The series then shifts to Milwaukee, where Bubba Chandler is the probable starter against Brandon Sproat on Monday, August 3.

Where the club stands

Third place in the NL Central, 21 games back, eliminated from the division and the Wild Card — the Pirates' 2026 postseason window has closed. What remains is a stretch of games that will shape how the organization evaluates its roster heading into the offseason, and potentially how it thinks about the players it is adding right now.

At 82-80, Pittsburgh is not a bad baseball team. A .506 winning percentage is a respectable outcome for a franchise that has spent much of the last decade rebuilding. The problem is that respectable and competitive are not the same thing in October, and the NL Central has not been kind to the Pirates' margin for error this year.

The upcoming series against Cincinnati and Milwaukee — two clubs the Pirates will need to measure themselves against in any honest assessment of where they stand — will tell the desk something about how this roster finishes. Whether Doval is part of that picture depends entirely on whether the medical review clears.

What we don't know yet

The report does not specify what Pittsburgh is sending to New York in exchange for Doval. The terms of the deal — prospects, players, financial considerations — have not been reported. It is also not known whether the medical review will clear without complication, which means the trade itself remains contingent.

The report does not address how Doval would be used in Pittsburgh's bullpen, what his role would look like, or how he fits into the club's roster construction given the 26-man active limit that runs through the end of August. Any roster moves that would be required to accommodate him have not been reported.

It is also worth noting that the Yankees are the other party here, and their motivations — whether this is a salary consideration, a prospect acquisition, or something else entirely — are not addressed in the report. A deal requires two sides to agree, and what New York gets out of this arrangement is, for now, unknown.

What to watch

The most immediate thing to monitor is whether either the Pirates or the Yankees make a formal announcement clearing the medical review. That announcement — if it comes — would move this from a reported transaction to a completed one, and would presumably include the terms of the deal that are currently absent from the reporting.

Beyond the transaction itself, watch how Pittsburgh deploys its bullpen over the final weeks of the season. A club that has been eliminated from playoff contention but is reportedly still adding relievers is signaling something about how it views the roster's trajectory — the report does not say what that trajectory looks like, but the activity itself is a data point.

The series in Cincinnati this weekend, with Ashcraft going Saturday and Keller on Sunday, will also be worth tracking. The Pirates are on a one-game winning streak, and how they perform against the Reds and then the Brewers will give some texture to what this roster looks like as it heads toward the offseason.

For now, the desk is watching the transaction wire and waiting for a formal announcement. A deal in medical review is a deal in progress — and in baseball, progress is not the same as completion.